Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Hematology

Can You Get Pregnant With Essential Thrombocythemia?

At a Glance

Many people with essential thrombocythemia have successful pregnancies, but the condition raises risks of blood clots, bleeding, miscarriage, and poor fetal growth. A hematologist and high-risk pregnancy specialist should tailor medicines, monitoring, delivery planning, and postpartum care.

Yes, many people with essential thrombocythemia (ET) have successful pregnancies, but the risks and treatment plan are highly individual. In published studies, live-birth rates for ET pregnancies are around 70% [1][2]. However, because ET can increase the risk of maternal blood clots, bleeding, and pregnancy complications like miscarriage or fetal growth restriction, your pregnancy will be considered “high-risk” [3][4]. This simply means you will need specialized monitoring and medication adjustments to protect your health and support your baby’s development.

To safely manage ET during pregnancy, you will need a collaborative care team consisting of your hematologist and a maternal-fetal medicine (MFM) specialist (an obstetrician who specializes in high-risk pregnancies) [5][6].

⚠️ Important Safety Note: Do not stop, start, or change any of your medications on your own. If you discover you are pregnant, contact your care team immediately to discuss a transition plan.

Medication Adjustments for Pregnancy

If you are planning to become pregnant, or discover you are pregnant, your hematologist will need to adjust your treatment plan.

  • Hydroxyurea and Anagrelide: These medications are generally avoided during pregnancy because fetal safety data are limited [7][5]. Additionally, anagrelide can increase bleeding risks, especially when combined with aspirin [8]. If you are planning a pregnancy, doctors typically recommend transitioning off hydroxyurea at least three months before trying to conceive [7].
  • Interferon-alpha (Pegylated Interferon): If your doctors determine that you need cytoreduction (medication to actively lower your platelet count) to keep your ET well-controlled during pregnancy, interferon-alpha is considered the preferred option. While pregnancy safety data for any medication is limited, interferon-alpha has reassuring clinical experience and effectively lowers platelet counts in pregnant women without harming the baby [9][10].
  • Low-Dose Aspirin: Many women with ET are prescribed low-dose aspirin during pregnancy. Observational studies have linked aspirin use in ET pregnancies with higher odds of a live birth [2][11]. However, do not start over-the-counter aspirin without your doctor’s approval. If your platelet counts are extremely high or you have a history of bleeding, your doctor may first test you for acquired von Willebrand syndrome (a bleeding tendency caused by high platelets) before recommending aspirin [12][13].
  • Heparin (LMWH): Low-molecular-weight heparin is an injectable blood thinner. It is not automatically required for every pregnant woman with ET. Your doctor may prescribe LMWH if you have a history of blood clots, prior severe pregnancy complications, or other high-risk factors [9][14].

What to Expect: Trimesters, Delivery, and Epidurals

During your pregnancy, your care team will closely monitor your blood counts, blood pressure, and your baby’s growth. Interestingly, as a population observation, platelet counts often naturally decline during pregnancy, sometimes dropping significantly by the third trimester [15][3]. However, a lower platelet count does not eliminate your clot risk, and management is based on your full clinical picture, not just this number.

As you approach your due date, your MFM specialist and hematologist will coordinate your delivery plan. If you are taking blood thinners like LMWH or aspirin, they will give you specific instructions on when to stop these medications before labor. This timing is critical to safely accommodate an epidural (neuraxial anesthesia) and minimize bleeding risks during delivery [13][16].

Postpartum Care and Breastfeeding

The postpartum period (the weeks immediately following delivery) requires careful attention. The risk of developing a blood clot temporarily increases after giving birth. Based on pooled observational data, the postpartum clot risk for ET patients is estimated around 4.4% [14]. Furthermore, platelet counts can rebound quickly after delivery [17].

To protect your health after the baby is born:

  • Postpartum Blood Thinners: Guidelines commonly suggest a short course of blood thinners (like LMWH) for at least 6 weeks after delivery to prevent blood clots [14][18]. The exact dose and duration will be individualized based on your delivery method and bleeding risks.
  • Monitoring: Your hematologist will closely track your platelet counts in the weeks following delivery to determine when or if you need to restart your regular ET medications [17][19].
  • Breastfeeding (Lactation): You must discuss your feeding plans with your doctor before delivery. Many ET medications (including hydroxyurea and anagrelide) are generally avoided while breastfeeding due to potential risks to the infant [7]. Your doctor will help you choose treatments that are compatible with lactation.

🚨 Emergency Warning Signs

Seek emergency medical care immediately if you experience any of the following, as they could indicate a blood clot, severe bleeding, or preeclampsia:

  • Sudden shortness of breath or chest pain
  • Swelling, warmth, or pain in one leg
  • Severe or persistent headaches, or sudden vision changes
  • Heavy or uncontrolled vaginal bleeding
  • Severe abdominal pain or noticeably reduced fetal movement

Common questions in this guide

Can I have a successful pregnancy if I have essential thrombocythemia?
Yes, many people with essential thrombocythemia have successful pregnancies, and studies report live-birth rates around 70%. ET increases the risks of blood clots, bleeding, miscarriage, and poor fetal growth, so pregnancy is treated as high risk and monitored by a hematologist and maternal-fetal medicine specialist.
Which essential thrombocythemia medicines can be used during pregnancy?
Hydroxyurea and anagrelide are generally avoided during pregnancy because fetal safety information is limited. If treatment is needed to lower platelets, interferon-alpha is usually the preferred option; aspirin or low-molecular-weight heparin may be added only when your clinicians decide the benefits outweigh the risks.
Will I need aspirin or heparin during an ET pregnancy?
No. Low-dose aspirin and low-molecular-weight heparin are not automatically required for every pregnancy with ET. The decision depends on factors such as a history of clots, severe prior pregnancy complications, bleeding risk, and platelet levels; very high platelets may prompt testing for acquired von Willebrand syndrome before aspirin.
What happens to my essential thrombocythemia after I give birth?
The postpartum period carries a temporary increase in clot risk, and platelet counts can rise quickly after delivery. Guidelines commonly suggest low-molecular-weight heparin for at least six weeks after birth, but the dose and duration depend on your delivery, bleeding risk, and history. Your hematologist will decide when to restart or adjust ET medicines.
Can I breastfeed while taking essential thrombocythemia treatment?
Breastfeeding plans should be discussed before delivery because hydroxyurea and anagrelide are generally avoided during lactation due to potential risks to the infant. Your care team can help choose an ET treatment that fits your feeding plans.
Can I receive an epidural if I have ET during pregnancy?
An epidural may be possible, but its safety depends on your blood counts and when you last took aspirin or low-molecular-weight heparin. Your hematologist and maternal-fetal medicine specialist should give exact instructions for stopping and restarting these medicines around delivery.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the plan for transitioning off my current ET medications before I try to conceive?
  2. 2.Based on my personal medical history and ET mutation, do you recommend I take low-dose aspirin or LMWH during pregnancy?
  3. 3.How will my bleeding risk be assessed, and should I be tested for acquired von Willebrand syndrome?
  4. 4.How often will you and my maternal-fetal medicine specialist collaborate to monitor my blood counts and fetal growth?
  5. 5.When exactly should I stop my blood thinners or aspirin prior to delivery to safely receive an epidural?
  6. 6.Which of my ET medications are safe to take if I choose to breastfeed my baby?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy.

    Griesshammer M, Sadjadian P, Wille K

    Expert review of hematology 2018; (11(9)):697-706 doi:10.1080/17474086.2018.1506325.

    PMID: 30084669
  2. 2

    Association of Treatments for Myeloproliferative Neoplasms During Pregnancy With Birth Rates and Maternal Outcomes: A Systematic Review and Meta-analysis.

    Maze D, Kazi S, Gupta V, et al.

    JAMA network open 2019; (2(10)):e1912666 doi:10.1001/jamanetworkopen.2019.12666.

    PMID: 31584685
  3. 3

    Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia.

    How J, Leiva O, Bogue T, et al.

    Leukemia research 2020; (98()):106459 doi:10.1016/j.leukres.2020.106459.

    PMID: 33022566
  4. 4

    Management and outcomes of 27 pregnancies in women with myeloproliferative neoplasms.

    Lapoirie J, Contis A, Guy A, et al.

    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2020; (33(1)):49-56 doi:10.1080/14767058.2018.1484097.

    PMID: 29945475
  5. 5

    Management of myeloproliferative neoplasms in pregnancy: Essential thrombocythemia, polycythemia vera, and primary myelofibrosis.

    Corrao K

    Seminars in hematology 2026; doi:10.1053/j.seminhematol.2026.06.005.

    PMID: 42552139
  6. 6

    How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy.

    Robinson SE, Harrison CN

    British journal of haematology 2020; (189(4)):625-634 doi:10.1111/bjh.16453.

    PMID: 32150650
  7. 7

    Safety of Hydroxyurea in Pregnancy: A Systematic Review of the Literature.

    Al Sulaimani R, Zitoun N, Alothman H, et al.

    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2025; (47(7)):102924 doi:10.1016/j.jogc.2025.102924.

    PMID: 40381805
  8. 8

    Hemorrhage in Essential Thrombocythemia or Polycythemia Vera: Epidemiology, Location, Risk Factors, and Lessons Learned from the Literature.

    Nicol C, Lacut K, Pan-Petesch B, et al.

    Thrombosis and haemostasis 2021; (121(5)):553-564 doi:10.1055/s-0040-1720979.

    PMID: 33186994
  9. 9

    Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations.

    Gangat N, Tefferi A

    American journal of hematology 2021; (96(3)):354-366 doi:10.1002/ajh.26067.

    PMID: 33296529
  10. 10

    Efficacy and safety of interferon alpha for essential thrombocythemia during pregnancy: two cases and a literature review.

    Sakai K, Ueda A, Hasegawa M, Ueda Y

    International journal of hematology 2018; (108(2)):203-207 doi:10.1007/s12185-017-2397-8.

    PMID: 29290077
  11. 11

    Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.

    Tefferi A, Barbui T

    American journal of hematology 2015; (90(2)):162-73 doi:10.1002/ajh.23895.

    PMID: 25611051
  12. 12

    Topics of Interest in Women With Myeloproliferative Neoplasms.

    Szuber N, Guglielmelli P, Gangat N

    American journal of hematology 2025; (100 Suppl 4()):74-87 doi:10.1002/ajh.27665.

    PMID: 40084464
  13. 13

    The course of acquired von Willebrand syndrome during pregnancy among patients with essential thrombocytosis.

    Rottenstreich A, Kleinstern G, Amsalem H, Kalish Y

    Journal of thrombosis and thrombolysis 2018; (46(3)):304-309 doi:10.1007/s11239-018-1663-9.

    PMID: 29654448
  14. 14

    Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis.

    Skeith L, Carrier M, Robinson SE, et al.

    Blood 2017; (129(8)):934-939 doi:10.1182/blood-2016-09-728006.

    PMID: 28049641
  15. 15

    Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2- and CALR-mutated essential thrombocythemia-A Mayo Clinic study of 200 pregnancies.

    Gangat N, Singh A, Ilyas R, et al.

    American journal of hematology 2024; (99(10)):1862-1869 doi:10.1002/ajh.27416.

    PMID: 38867546
  16. 16

    Postpartum haemorrhage in a woman with essential thrombocythemia carrying calreticulin mutation: a case report.

    Villani M, Colaizzo D, Tiscia GL, et al.

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2016; (27(6)):727-8 doi:10.1097/MBC.0000000000000473.

    PMID: 26650457
  17. 17

    Marked Rebound of Platelet Count in the Early Postpartum Period in a Patient with Essential Thrombocythemia.

    Hashimoto Y, Hosoda R, Omura H, Tanaka T

    Case reports in hematology 2021; (2021()):6633790 doi:10.1155/2021/6633790.

    PMID: 33614173
  18. 18

    Esssential thrombocythaemia and pregnancy-A need for prospective study and a consensus on its management.

    Burbury K, Panigrahi A

    Leukemia research 2021; (102()):106500 doi:10.1016/j.leukres.2021.106500.

    PMID: 33556743
  19. 19

    Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera.

    How J, Hobbs G

    Current hematologic malignancy reports 2021; (16(5)):473-482 doi:10.1007/s11899-021-00649-x.

    PMID: 34478054

This page is for informational purposes only and does not constitute medical advice about pregnancy with essential thrombocythemia. Do not change medicines or start aspirin or blood thinners without guidance from your hematologist and maternal-fetal medicine specialist.

Get notified when new evidence is published on Essential thrombocythemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.